AngioDynamics grants sign-on stock awards to new CEO Eric Honroth
ANGO•AngioDynamics granted CEO Eric Honroth time- and performance-based restricted stock units, including 62,928 shares at target for each of two awards and another 38,265 time-based units.
1. Stock awards
AngioDynamics granted Eric Honroth sign-on restricted stock units on November 2, 2026, effective with his appointment as CEO. One award covers 62,928 shares and vests in equal annual installments over four years, subject to continued service. A performance-based award covers 62,928 shares at target, with payouts ranging from 0% to 240% of target, based on three-year revenue, adjusted EBITDA and relative total shareholder return targets. Another 38,265 time-based units vest equally on November 2, 2027, and November 2, 2028, subject to continued service.
